Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Current Assets (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Current Assets over the past 12 years, most recently at $894.2 million for Q4 2025.

  • Quarterly results put Current Assets at $894.2 million for Q4 2025, up 21.09% from a year ago — trailing twelve months through Dec 2025 was $894.2 million (up 21.09% YoY), and the annual figure for FY2025 was $894.2 million, up 21.09%.
  • Current Assets for Q4 2025 was $894.2 million at Viridian Therapeutics, Inc.\DE, up from $571.9 million in the prior quarter.
  • Over the last five years, Current Assets for VRDN hit a ceiling of $894.2 million in Q4 2025 and a floor of $115.5 million in Q2 2021.
  • Median Current Assets over the past 5 years was $434.3 million (2022), compared with a mean of $441.2 million.
  • Biggest five-year swings in Current Assets: skyrocketed 581.66% in 2021 and later dropped 25.96% in 2023.
  • Viridian Therapeutics, Inc.\DE's Current Assets stood at $200.2 million in 2021, then surged by 115.41% to $431.2 million in 2022, then rose by 12.83% to $486.5 million in 2023, then skyrocketed by 51.8% to $738.5 million in 2024, then increased by 21.09% to $894.2 million in 2025.
  • The last three reported values for Current Assets were $894.2 million (Q4 2025), $571.9 million (Q3 2025), and $578.8 million (Q2 2025) per Business Quant data.